vasoactive-intestinal-peptide and Diabetic-Angiopathies

vasoactive-intestinal-peptide has been researched along with Diabetic-Angiopathies* in 2 studies

Reviews

1 review(s) available for vasoactive-intestinal-peptide and Diabetic-Angiopathies

ArticleYear
[Sexual functions and reproduction in diabetics].
    Journees annuelles de diabetologie de l'Hotel-Dieu, 1984

    Topics: Adrenocorticotropic Hormone; Adult; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Neuropathies; Erectile Dysfunction; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Infertility; Luteinizing Hormone; Male; Melanocyte-Stimulating Hormones; Middle Aged; Prolactin; Reproduction; Sexual Dysfunction, Physiological; Thyrotropin-Releasing Hormone; Urodynamics; Vasoactive Intestinal Peptide

1984

Other Studies

1 other study(ies) available for vasoactive-intestinal-peptide and Diabetic-Angiopathies

ArticleYear
Granulocyte colony-stimulating factor provides protection against cardiovascular autonomic neuropathy in streptozotocin-induced diabetes in rats.
    Diabetes research and clinical practice, 2015, Volume: 107, Issue:3

    Cardiovascular autonomic neuropathy (CAN) is a relatively common and detrimental complication of diabetes mellitus (DM). Dysregulation of neuropeptides, such as calcitonin gene-related peptide (CGRP) and vasoactive intestinal peptide (VIP), are thought to play significant roles in diabetes-related cardiovascular disease. Accumulating evidence indicates the neuroprotective effects of granulocyte-colony stimulating factor (G-CSF) in different neurological disorders. The purpose of the study is to investigate the role of CGRP and VIP and possible effects of G-CSF on CAN in type I DM model in rats.. Diabetes was induced by intraperitoneal injection of streptozotocin (STZ) for 14 rats. Seven rats served as controls and 6 rats were administered G-CSF alone. DM group was randomly divided into 2 groups and received either 1mL/kg saline (DM+saline group) or 100 μg/kg/day G-CSF (DM+G-CSF group) for 4 weeks. Following electrocardiography (ECG), GCRP and VIP levels were measured in plasma samples.. Diabetes promoted a significant prolongation in the corrected QT interval (cQT) (P<0.001) whereas G-CSF administration significantly shortened cQT interval (P<0.05). Plasma VIP and CGRP levels of saline treated DM group were significantly lower than those of control group (P<0.05). G-CSF treatment significantly prevented the reduction in plasma VIP and CGRP levels (P<0.01 and P<0.05, respectively). Also, correlation analysis showed a significant negative correlation between the cQT and neuropeptide levels.. This study suggests that G-CSF can be effective in CAN by means of neuroprotection, and plasma VIP and CGRP levels can be used for the assessment of autonomic and sensory functions in diabetes.

    Topics: Animals; Calcitonin Gene-Related Peptide; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Diabetic Neuropathies; Granulocyte Colony-Stimulating Factor; Male; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Streptozocin; Vasoactive Intestinal Peptide

2015